QuantaLife receives grant to develop technology for MSRA detection

Polymerase chain reaction (PCR) developer QuantaLife has received a National Institutes of Health (NIH) grant totaling ~$6 million over five years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections.

Polymerase chain reaction (PCR) developer QuantaLife (Pleasanton, CA) has received a National Institutes of Health (NIH) grant totaling ~$6 million over five years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections. The grant, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the NIH, will fund the project.

QuantaLife is currently building a new instrument system for droplet digital PCR that will detect and quantify DNA/RNA targets. The NIH grant will allow the company to broaden its product pipeline to build a platform for detecting the antibiotic-resistant bacteria that cause MRSA infections. Clinical testing will be done in collaboration with the University of Mississippi Medical Center.

Source: PR Newswire

Posted by Lee Mather

Follow us on Twitter

Subscribe now to BioOptics World Magazine; it's free!

More in Biomedicine